Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
1.68 USD -3.45% Intraday chart for Lexicon Pharmaceuticals, Inc. -9.19% +9.80%
21/06 Sector Update: Health Care Stocks Gain in Late Afternoon MT
21/06 Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy MT

Business Summary

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Number of employees: 285

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
0 100.0 % 1 100.0 % +766.19%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 1 100.0 % +766.19%

Managers

Managers TitleAgeSince
Lonnel Coats CEO
 Chief Executive Officer 58 07/14/07
Jeffrey Wade DFI
 Director of Finance/CFO 59 01/99/01
Craig Granowitz CTO
 Chief Tech/Sci/R&D Officer 60 02/21/02
Lisa M. DeFrancesco IRC
 Investor Relations Contact 45 13/11
Tom Garner PRN
 Corporate Officer/Principal - 09/23/09
Wendy Mcdermott HRO
 Human Resources Officer - 01/22/01
Kristen Alexander AUD
 Comptroller/Controller/Auditor 56 01/17/01
Kenneth Kassler-Taub LAW
 General Counsel - 04/14/04
Brian Crum LAW
 General Counsel 51 01/01/01

Members of the board

Members of the board TitleAgeSince
Robert Lefkowitz BRD
 Director/Board Member 80 01/01/01
Ray Debbane CHM
 Chairman 69 01/07/01
Christopher Sobecki BRD
 Director/Board Member 65 28/07/28
Philippe Amouyal BRD
 Director/Board Member 65 01/07/01
Judith Swain BRD
 Director/Board Member 75 01/07/01
Lonnel Coats CEO
 Chief Executive Officer 58 07/14/07
Samuel Barker BRD
 Director/Board Member 81 01/00/01
Diane Sullivan BRD
 Director/Board Member 62 28/23/28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 362,972,111 357,294,841 ( 98.44 %) 1,528,008 ( 0.4210 %) 98.44 %
Stock B 0 2,304,147 0 0

Shareholders

NameEquities%Valuation
Invus Public Equities Advisors LLC
48.44 %
175,099,384 48.44 % 298 M $
Artal Group SA
32.52 %
117,553,284 32.52 % 200 M $
Fidelity Management & Research Co. LLC
3.844 %
13,894,062 3.844 % 24 M $
BlackRock Advisors LLC
2.022 %
7,311,030 2.022 % 12 M $
Vanguard Fiduciary Trust Co.
1.771 %
6,401,225 1.771 % 11 M $
OrbiMed Advisors Private Equity
0.9798 %
3,542,000 0.9798 % 6 M $
Geode Capital Management LLC
0.6609 %
2,389,137 0.6609 % 4 M $
NEA Management Co. LLC
0.6590 %
2,382,286 0.6590 % 4 M $
STATE STREET CORPORATION
0.5498 %
1,987,510 0.5498 % 3 M $
Pinnacle Associates Ltd.
0.4835 %
1,747,830 0.4835 % 3 M $

Company contact information

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard 11th floor

77381-1160, The Woodlands

+

http://www.lexpharma.com
address Lexicon Pharmaceuticals, Inc.(LXRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.68 USD
Average target price
6.2 USD
Spread / Average Target
+269.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEXICON PHARMACEUTICALS, INC. Stock Lexicon Pharmaceuticals, Inc.
+9.80% 607M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Company Lexicon Pharmaceuticals, Inc.